上 市 公 司 医药生物 2025 年 06 月 26 日 上海医药 (02607) ——流通+工业双轮驱动，全产业链系统释放创新价值 报告原因：首次覆盖 买入（首次评级） | 市场数据： | 2025 年 06 月 25 日 | | --- | --- | | 收盘价（港币） | 11.92 | | 恒生中国企业指数 | 8859.29 | | 52 周最高/最低（港币） | 14.70/10.04 | | H 股市值（亿港币） | 442.04 | | 流通 H 股（百万股） | 919.07 | | 汇率（人民币/港币） | 1.0953 | 一年内股价与基准指数对比走势： -10% 40% 90% 06/25 07/25 08/25 09/25 10/25 11/25 12/25 01/25 02/25 03/25 04/25 05/25 06/25 HSCEI 上海医药 资料来源：Bloomberg 证券分析师 张静含 A0230522080004 zhangjh@swsresearch.com 余玉君 A0230522080005 yuyj@swsresearch.com 李敏杰 A0230523 ...

如何以提高上市公司发展质量为抓手，全力培育和打造一批经营业绩佳、创新能力强、治理体系优、市场认可 度高的一流上市公司？ 5月9日，上海市国资委联合上海证券交易所，共同举办了上海国有控股上市公司2024年度集体业绩说明会，以 推动上海市国有控股上市公司在做强做优做大、提升内在价值的同时，进一步强化投资者关系管理、提高信息 透明度、增进市场认同。 本次业绩说明会上，上港集团、华谊集团、上海医药、浦发银行、中国太保、数据港等6家在上交所挂牌的上 海国有控股上市公司，全方位展示了各自在经营发展、产业布局、技术创新、ESG建设、投资者回报等方面的 成效与未来规划。 近年来，上海市国资委持续加强上海市国有控股上市公司市值管理工作，通过强化政策引领、实施重点领域资 本运作项目、加速国资基金设立及运作、稳妥开展风险防范和处置等举措，助推上市公司提质增效，稳步提升 经营效率和盈利能力。截至2024年末，上海市94家国有控股上市公司总市值2.78万亿元，较年初增加6177.74亿 元，增长28.52%。 今年是"十四五"规划和国企改革深化提升行动的"双收官"之年，也是"十五五"谋篇布局之年。上海市国资委表 示，下一步，上海国资国 ...

Core Insights - Shanghai Pharmaceuticals reported a solid performance in Q1 2025, achieving a revenue of 70.763 billion yuan, a year-on-year increase of 0.87%, with a net profit attributable to shareholders of 1.333 billion yuan and R&D investment of 0.612 billion yuan [1] Pharmaceutical Industry Segment - The company made progress in R&D with multiple product approvals and advancements in innovative drug development and traditional Chinese medicine projects [2] - Key clinical trials for several innovative drugs are ongoing, including I001 for hypertension and B001 for neuromyelitis optica spectrum disorder, with significant patient enrollment completed [2] - The establishment of several research centers in Shanghai enhances the collaborative R&D framework [2] - New products launched include ursodeoxycholic acid capsules and omeprazole sodium bicarbonate suspension, with additional products submitted for production approval [2] - The company has achieved consistency evaluation for 77 products, totaling 106 specifications [2] Traditional Chinese Medicine Business - The company is advancing the secondary development of major traditional Chinese medicine products, with significant progress in evidence-based research [3] - Collaboration with Tianjin University of Traditional Chinese Medicine has led to published research and recognition for quality improvement in traditional Chinese medicine [3] - A comprehensive strategy for securing quality medicinal materials from the source is being implemented, focusing on digital transformation and standardized management [3] Pharmaceutical Commercial Segment - The company achieved a sales revenue of 8.6 billion yuan from its import agency business, reflecting a year-on-year growth of 9.0% [4] - The establishment of a drug and medical device import-export service center in the Lingang New Area supports the import of urgently needed drugs and rare disease medications [4] - Strategic partnerships with companies like AstraZeneca and CanSino Biologics have been formed to enhance the commercialization of new drugs, with innovative drug business revenue reaching 12.5 billion yuan, a growth of 23.2% [4] - The medical device health business generated 10.9 billion yuan in sales, marking a 6.9% increase [4] - The company aims to leverage its full industry chain resources and collaborate with academic and research institutions to foster innovation and enhance competitiveness [4]